Login / Signup

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.

Massimo BrecciaGioia ColafigliMatteo MolicaEmilia ScalzulliDaniela DiverioRoberto LatagliataAnna GuariniRobin Foà
Published in: American journal of hematology (2017)
Keyphrases
  • chronic myeloid leukemia
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • combination therapy